Plain-English translation of NCT03356808 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called CAR T cell therapy, where doctors take immune cells from your blood, train them in a lab to recognize and attack lung cancer cells, and then give them back to you through an infusion. The goal is to see whether this personalized immune treatment is safe and effective for people with advanced lung cancer.
Standard treatments like chemotherapy and radiation don't always work well for people whose lung cancer has come back or stopped responding to these therapies. This trial exists to explore whether boosting your own immune system with specially engineered cells could offer a new option for patients who have run out of conventional treatment choices.
First, doctors will collect immune cells from your blood using a process called apheresis, which is similar to donating plasma. These cells will then be sent to a lab where they are grown and genetically modified to recognize your specific cancer cells. After the cells are ready, you will receive them back through an intravenous infusion. The trial will then monitor you closely to see how the treatment works, how long the cells survive in your body, and what side effects you experience.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China